Initial 100 consecutive stereotactic core breast biopsies in a private breast center setting.
Percutaneous stereotactic core biopsy has become an alternative to open surgical biopsy. We report the initial 100 consecutive stereotactic core breast biopsies performed in a private breast center by three surgeons. Of the lesions biopsied, 89 were benign and 11 were malignant. Histological agreement was found in ten malignant and eight benign lesions that subsequently underwent open biopsy. In one patient with a lesion read as sclerosing papilloma on stereotactic core biopsy, a subsequent open biopsy undertaken at the pathologist's urging yielded a low-grade ductal carcinoma in situ. Stereotactic core breast biopsy is safe, accurate, cost-effective, and minimally invasive. It will, in all likelihood, become the breast biopsy method of choice.